Drug targets for cognitive enhancement in neuropsychiatric disorders.

Wallace, Tanya L., Ballard, Theresa M., Pouzet, Bruno, Riedel, Wim J., Wettstein, Joseph G.·2011·Pharmacology Biochemistry and Behavior
DOI 10.1016/j.pbb.2011.03.022

Cites (253)

Items 201–251 of 251

  1. Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia
    Taryn G. Moss, Kristi A. Sacco, Taryn M. Allen, Andrea H. Weinberger, Jennifer C. Vessicchio, Tony Peter George · 2009 · Drug and Alcohol Dependence
  2. Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice
    Andrea L.O. Hebb, H.A. Robertson, Eileen M. Denovan‐Wright · 2007 · European Neuropsychopharmacology
  3. PWZ-029, a compound with moderate inverse agonist functional selectivity at GABAA receptors containing α5 subunits, improves passive, but not active, avoidance learning in rats
    Miroslav M. Savić, Terry Clayton, Roman Furtmüller, Ivana Gavrilović, Janko Samardžić, Snezana D. Savic, Sigismund Huck, Werner Sieghart, James Minton Cook · 2008 · Brain Research
  4. Association of a haplotype in the serotonin 5‐HT4 receptor gene (HTR4) with Japanese schizophrenia
    Taroh Suzuki, Nakao Iwata, Y. Kitamura, Tsuyoshi Kitajima, Yoshio Yamanouchi, Masashi Ikeda, T. Nishiyama, Naoyuki Kamatani, Norio Ozaki · 2003 · American Journal of Medical Genetics Part B Neuropsychiatric Genetics
  5. Glycine transporter inhibition reverses ketamine-induced working memory deficits
    Brooke M. Roberts, Christopher L. Shaffer, Patricia A. Seymour, Christopher J. Schmidt, Graham V. Williams, Stacy A. Castner · 2010 · Neuroreport
  6. The Effect of Apomorphine and Buspirone on Regional Cerebral Blood Flow During the Performance of a Cognitive Task—Measuring Neuromodulatory Effects of Psychotropic Drugs in Man
    Paul M. Grasby, Karl John Friston, C.J. Bench, Chris Frith, Eraldo Paulesu, Philip J. Cowen, Peter Francis Liddle, Richard S. J. Frackowiak, Raymond J. Dolan · 1992 · European Journal of Neuroscience
  7. Selective serotonin 5-HT2A receptor antagonist EMD 281014 improves delayed matching performance in young and aged rhesus monkeys
    Alvin V. Terry, Jerry J. Buccafusco, Gerd D. Bartoszyk · 2004 · Psychopharmacology
  8. The Pharmacology of the Neurochemical Transmission in the Midbrain Raphe Nuclei of the Rat
    László Gábor Hársing · 2006 · Current Neuropharmacology
  9. Effects of mGlu2 or mGlu3 receptor deletions on mGlu2/3 receptor agonist (LY354740)-induced brain c-Fos expression: Specific roles for mGlu2 in the amygdala and subcortical nuclei, and mGlu3 in the hippocampus
    Anni-Maija Linden, Melvin Baez, Marcelle Bergeron, Darryle D. Schoepp · 2006 · Neuropharmacology
  10. Endogenous Neurotensin in the Ventral Tegmental Area Contributes to Amphetamine Behavioral Sensitization
    Fany Panayi, Joyce Colussi‐Mas, Laura Lambás‐Señas, Bernard Renaud, Hélène Scarna, Anne Bérod · 2004 · Neuropsychopharmacology
  11. Sildenafil (Viagra®): Is there an influence on psychological performance?
    H. Graß, T. Koltz, B. FATHIAN-SABET, G Berghaus, Udo Horst Engelmann, Herbert Käferstein · 2001 · International Urology and Nephrology
  12. The effect of (±)-CP-101,606, an NMDA receptor NR2B subunit selective antagonist, in the Morris watermaze
    Martin R. Guscott, Hannah F. Clarke, Fraser Murray, Sarah Grimwood, Linda J. Bristow, Peter H. Hutson · 2003 · European Journal of Pharmacology
  13. The effects of a benzodiazepine receptor antagonist β-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills
    Theodora Duka, H. Ott, A. Rohloff, Bernard Voet · 1996 · Psychopharmacology
  14. Blockade of the metabotropic glutamate 2/3 receptors enhances social memory via the AMPA receptor in rats
    Toshiharu Shimazaki, Ayaka Kaku, Shigeyuki Chaki · 2007 · European Journal of Pharmacology
  15. From science to application: the development of an intervention package.
    Susan M. Kegeles, Greg Rebchook, Robert B. Hays, Martha Ann Terry, Lydia N. O’Donnell, Noelle R. Leonard, Jeffrey A. Kelly, Mary Spink Neumann · 2000 · PubMed
  16. The Metabotropic Glutamate (mGLU)2/3 Receptor Antagonist LY341495 [2 S-2-Amino-2-(1 S,2 S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic Acid] Stimulates Waking and Fast Electroencephalogram Power and Blocks the Effects of the mGLU2/3 Receptor Agonist LY379268 [(-)-2-Oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate] in Rats
    Irwin Feinberg, Darryle D. Schoepp, K.-C. Hsieh, Nato Darchia, Ian Glenn Campbell · 2005 · Journal of Pharmacology and Experimental Therapeutics
  17. Metabotropic Glutamate Receptors as Therapeutic Targets for Cognitive Disorders
    Andreas Gravius, Malgorzata Pietraszek, Andrzej Dekundy, Wojciech Danysz · 2010 · Current Topics in Medicinal Chemistry
  18. Treatment of negative and cognitive symptoms
    Daniel C. Javitt · 1999 · Current Psychiatry Reports
  19. Association of attention-deficit/hyperactivity disorder with serotonin 4 receptor gene polymorphisms in Han Chinese subjects.
    Jun Li, Yu-Feng Wang, R. Zhou, Bing Wang, Hao-bo Zhang, Li Yang, S. Faraone · 2006 · Neuroscience Letters
  20. Characterization of (2S,2′R,3′R)‐2‐(2′,3′‐[3H]‐Dicarboxycyclopropyl)glycine Binding in Rat Brain
    Vincent Mutel, Geo Adam, Sylvie Chaboz, John A. Kemp, Agnès Klingelschmidt, Jürg Messer, Jürgen Wichmann, Thomas J. Woltering, John Grayson Richards · 1998 · Journal of Neurochemistry
  21. Reversal of Ketamine-Induced Working Memory Impairments by the GABAAα2/3 Agonist TPA023
    Castner, Stacy A., Arriza, Jeffrey L., Roberts, John C., Mrzljak, Ladislav, Christian, Edward P., Williams, Graham V. · 2010 · Biological Psychiatry
  22. Effects of D-Cycloserine Administration on Weekly Nonemotional Memory Tasks in Healthy Participants
    Michael W. Otto, Shawnee L. Basden, R. Kathryn McHugh, Kathleen M. Kantak, Thilo Deckersbach, Corinne Cather, DONALD C. GOFF, Stefan G. Hofmann, Angela C. Berry, Jasper A. J. Smits · 2008 · Psychotherapy and Psychosomatics
  23. Sedation and memory: studies with a histamine H-1 receptor antagonist
    Claire Turner, Alison D. F. Handford, Anthony N. Nicholson · 2006 · Journal of Psychopharmacology
  24. The 5-HT1A receptor and recognition memory
    Nikolaos Pitsikas, Stavroula Tsitsirigou, Styliani Zisopoulou, Nikos Sakellaridis · 2004 · Behavioural Brain Research
  25. Antipsychotic‐like profile of thioperamide, a selective H3‐receptor antagonist in mice
    Mohd Akhtar, P. Uma Devi, Atif Ali, K.K. Pillai, Divya Vohora · 2006 · Fundamental and Clinical Pharmacology
  26. Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea.
    Marwan Noel Sabbagh, Holly A. Shill · 2010 · PubMed
  27. Single dose human pharmacology of umespirone
    R.L. Holland, Keith Andrew Wesnes, Barbara Dietrich · 1994 · European Journal of Clinical Pharmacology
  28. A comparison of GMS‐A/AGECAT, DSM‐III‐R for dementia and depression, including subthreshold depression (SD)—results from the Berlin Aging Study (BASE)
    Rainer Schaub, M. Linden, J. R. M. Copeland · 2003 · International Journal of Geriatric Psychiatry
  29. Benzodiazepine receptor antagonists flumazenil and CGS 8216 and inverse-agonist β-CCM nhance spatial learning in the rat: Dissociation from anxiogenic actions
    Robert K. McNamara, Ronald W. Skelton · 1993 · Psychobiology
  30. Cognitive domains affected by histamine H1-antagonism in humans: A literature review
    Peter van Ruitenbeek, Annemiek Vermeeren, Wim J. Riedel · 2010 · Brain Research Reviews
  31. Histamine H 1 -receptor blockade in humans affects psychomotor performance but not memory
    Peter van Ruitenbeek, Annemiek Vermeeren, Wim J. Riedel · 2008 · Journal of Psychopharmacology
  32. Performance of automated slidemakers and stainers in a working laboratory environment – routine operation and quality control
    Elkin Simson, M. G. GASCON‐LEMA, D. L. BROWN · 2009 · International Journal of Laboratory Hematology
  33. Histamine H1 receptor antagonist cetirizine impairs working memory processing speed, but not episodic memory
    Peter van Ruitenbeek, Annemiek Vermeeren, Wim J. Riedel · 2010 · British Journal of Pharmacology
  34. Interactions between the glycine transporter 1(GlyT1) inhibitor SSR504734 and psychoactive drugs in mouse motor behaviour
    Philipp Singer, Joram Feldon, Benjamin K. Yee · 2009 · European Neuropsychopharmacology
  35. What can we Learn from the Disrupted in Schizophrenia 1 Interactome: Lessons for Target Identification and Disease Biology?
    Luiz Miguel Camargo, Qi Wang, Nicholas J. Brandon · 2008 · Novartis Foundation symposium
  36. Enhanced passive avoidance retention following posttrain serotonergic receptor antagonist administration in middle-aged and aged rats
    Howard J. Normile, Harvey J. Altman · 1988 · Neurobiology of Aging
  37. Phosphodiesterase Targets for Cognitive Dysfunction and Schizophrenia--a New York Academy of Sciences Meeting.
    Han-Ting Zhang · 2010 · PubMed
  38. Effects of L‐histidine depletion and L‐tyrosine/L‐phenylalanine depletion on sensory and motor processes in healthy volunteers
    Peter van Ruitenbeek, Anke Sambeth, Annemiek Vermeeren, Simon N. Young, Wim J. Riedel · 2009 · British Journal of Pharmacology
  39. Participation of D1–4 dopamine receptors in the pro-cognitive effects of angiotensin IV and des-Phe6 angiotensin IV
    Jan Józef Braszko · 2009 · Neuroscience & Biobehavioral Reviews
  40. Histamine-selective H3 receptor ligands and cognitive functions: an overview.
    Divya Vohora · 2004 · PubMed
  41. Event-related potentials in a passive and active auditory condition: effects of diazepam and buspirone on slow wave positivity
    Agnieszka Unrug, E.L.J.M. van Luijtelaar, MICHAEL G. H. COLES, A.M.L. Coenen · 1997 · Biological Psychology
  42. Histamine H1 receptor blockade predominantly impairs sensory processes in human sensorimotor performance
    Peter van Ruitenbeek, Annemiek Vermeeren, Fren T.Y. Smulders, Anke Sambeth, Wim J. Riedel · 2009 · British Journal of Pharmacology
  43. 2. Histaminergic mechanisms in the CNS
    Gerard B. Fox, T. A. Esbenshade, Jia Bao Pan, K. E. Browman, M. Zhang, Michael E. Ballard, Richard J. Radek, Holly M. Miner, Robert S. Bitner, Kathleen M. Krueger et al. · 2005 · Inflammation Research
  44. [Memory and dementia].
    Bernard Laurent, Catherine Thomas-Antérion, Ricardo Allegri · 1998 · PubMed
  45. Memory in humans is unaffected by central H1-antagonism, while objectively and subjectively measured sedation is increased
    Peter van Ruitenbeek, Annemiek Vermeeren, Wim J. Riedel · 2010 · European Neuropsychopharmacology
  46. Site-Selective N-Methyl-?-Aspartate and α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionate Antagonists Produce Distinct Effects in Rats Performing Complex Discriminations
    Catherine B. Willmore · 2002 · Neurobiology of Learning and Memory
  47. Flesinoxan improves cognition in the healthy elderly
    Jaap van Harten, Miranda Olff, Keith Andrew Wesnes, W. Strobel · 1996 · European Neuropsychopharmacology
  48. Differences in pharmacological properties of histamine H3 receptor agonists and antagonists revealed at two human H3 receptor isoforms
    T. A. Esbenshade, Kathleen M. Krueger, B. B. Yao, David G. Witte, Brian R. Estvander, John L. Baranowski, T. R. Miller, Arthur A. Hancock · 2006 · Inflammation Research
  49. Age-gender study of SRA-333, a novel 5-HT antagonist
    Alain A. Patat, Virginia Parks, S RAJE, Anna Plotka, Barbara Dietrich · 2005 · Clinical Pharmacology & Therapeutics
  50. New anticonvulsive compounds of sulfonamide derivatives line
    H.T. Zlenko, В. Й. Мамчур, Л. И. Касьян, O. Krasnovskaja, Andrey O. Kasyan, V. Butchenko, H. Demchenko, V. I. Opryshko · 1996 · European Neuropsychopharmacology
  51. No kinetic or dynamic interaction between flesinoxan and fluoxetine
    Jaap van Harten, Keith Andrew Wesnes, W. Strobel · 1996 · European Neuropsychopharmacology